MSLN and ovarian cancer: CAR-iMACS cells designed against CD19 and mesothelin were co-cultured with CD19+ K562 human leukaemic cells, mesothelin+ OVCAR3 human ovarian cancer cells, or mesothelin+ ASPC1 human pancreatic cancer cells.